YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Regulatory Effects of Cyclic AMP on Osteoclast Formation

조골세포내 cAMP 농도 변화가 파골세포 형성에 미치는 영향

  • Chun Yunna (College of Pharmacy, Sookmyung Women's University) ;
  • Yim Mijung (College of Pharmacy, Sookmyung Women's University)
  • 전윤나 (숙명여자대학교 약학대학) ;
  • 임미정 (숙명여자대학교 약학대학)
  • Published : 2005.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

In the present study treatment of IBMX, a phosphodiesterase (PDE) inhibitor, alone induced osteoclast formation in co-cultures of mouse bone marrow cells and calvarial osteoblasts. However, treatment of IBMX in combination with prostaglandin $E_2\;(PGE_2)$ inhibited osteoclast formation in a dose-dependent manner. Among various isozyme-specific PDE inhibitors, a PDE4 specific inhibitor, rolipram, showed similar effects as IBMX on osteoclast formation. To address the involvement of cyclic adenosine monophosphate (cAMP) in osteoclast formation, cAMP concentration in calvarial osteoblasts was investigated. When calvarial osteoblasts were co-cultured with IBMX alone or in combination with $PGE_2$, the patterns of cAMP concentration in calvarial osteoblasts were differ each other suggesting that cAMP in calvarial osteoblasts subtly regulates osteoclast formation.

Keywords

References

  1. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600 (1988) https://doi.org/10.1210/endo-123-5-2600
  2. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999) https://doi.org/10.1210/er.20.3.345
  3. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S. 3rd, Frankel, W. N., Lee, S. Y. and Choi, Y. : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190 (1997) https://doi.org/10.1074/jbc.272.40.25190
  4. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597 (1998)
  5. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165 (1998) https://doi.org/10.1016/S0092-8674(00)81569-X
  6. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P. and Boyle, W. J. : Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309 (1997) https://doi.org/10.1016/S0092-8674(00)80209-3
  7. Kondo, H., Guo, J. and Bringhurst, F. R. : Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17, 1667 (2002) https://doi.org/10.1359/jbmr.2002.17.9.1667
  8. Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M. and Chihara, K. : Prostaglandin $E_2$ stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res. 11, 62 (1996) https://doi.org/10.1002/jbmr.5650110110
  9. Fu, Q., Jilka, R. L., Manolagas, S. C. and O'Brien, C. A. : Parathyroid hormone stimulates receptor activator of $NF-{\kappa}B$ ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 277, 48868 (2002) https://doi.org/10.1074/jbc.M208494200
  10. Antoni, F. A. : Molecular diversity of cyclic AMP signaling. Front Neuroendocrinol. 21, 103 (2000) https://doi.org/10.1006/frne.1999.0193
  11. Essayan, D. M. : Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671 (2001) https://doi.org/10.1067/mai.2001.117052
  12. Kim, M., Chun, Y. and Yim, M. : Effect of pentoxifylline, a phosphodiesterase inhibitor, on osteoclast formation. Yakhak Hoeji 48, 197 (2004)
  13. Min, Y. K., Rao, Y., Okada, Y., Raisz, L. G. and Pilbeam, C. C : Regulation of prostaglandin G/H synthase-2 expression by interleuki-1 in human osteoblast-like cells. J. Bone Miner. Res. 13, 1066 (1998) https://doi.org/10.1359/jbmr.1998.13.7.1066
  14. Tetradis, S., Pilbeam, C. C., Liu, Y., Herschman, H. R. and Kream B. E. : Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3',5'-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 138, 3594 (1997) https://doi.org/10.1210/en.138.9.3594
  15. Miyaura, C., Inada, M., Matsumoto, C., Ohshiba, T., Uozumi, N., Shimizu, T. and Ito, A. : An essential role of cytosolic phospholipase A2alpha in prostaglandin $E_2$-mediated bone resorption associated with inflammation. J. Exp. Med. 197, 1303 (2003) https://doi.org/10.1084/jem.20030015